Article Text

Download PDFPDF
Correspondence on ‘Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study’
  1. Julien Maquet1,2,
  2. Margaux Lafaurie2,3,4,
  3. Laurent Sailler1,2,4,
  4. Maryse Lapeyre-Mestre2,3,4,
  5. Guillaume Moulis1,2,4
  1. 1 Internal Medicine, University Hospital Centre Toulouse, Toulouse, Occitanie, France
  2. 2 CIC 1436, University Hospital Centre Toulouse, Toulouse, Occitanie, France
  3. 3 Clinical Pharmacology, University Hospital Centre Toulouse, Toulouse, Occitanie, France
  4. 4 UMR 1027, INSERM - University of Toulouse, Toulouse, France
  1. Correspondence to Julien Maquet, Internal Medicine, University Hospital Centre Toulouse, Toulouse 31300, France; maquet.j{at}chu-toulouse.fr

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with great interest the articles by Zhu et al 1 and Mo et al 2 studying the risk of new systemic lupus erythematosus (SLE) diagnosis after immune thrombocytopenia (ITP) and autoimmune haemolytic anaemia (AIHA) diagnoses in the Taiwanese National Health Database. Zhu et al observed 34 SLE cases among 723 patients with incident ITP between 2000 and 2013. The 1-year and 5-year cumulative incidences were 1.9% and 4.8%, respectively.1 Mo et al reported the diagnosis of 117 SLE during the follow-up of 731 patients with incident AIHA between 2005 and 2012. The 1-year and 5-year cumulative incidences were 11.3% and 17.3%, respectively.2

In the present study, we estimated the risk of new SLE after incident ITP or AIHA in the entire French general population. FAITH and AHEAD cohorts3 are the French nationwide cohorts of adult patients with incident primary ITP and AIHA, respectively. These cohorts are built using validated algorithms in the French health database (Système National des Données de Santé), which links sociodemographic, out-hospital and in-hospital data for the entire French population (>66 million inhabitants).4 SLE was defined by the date of first in-hospital or chronic disease …

View Full Text

Footnotes

  • Contributors JM, ML and GM designed the study, carried out the data management and statistical analyses and wrote the paper. LS wrote the protocol of the FAITH cohort. GM wrote the protocol of the AHEAD cohort. All authors participated in the interpretation of the results, critically reviewed the manuscript and gave final approval for submission.

  • Funding This study is academic, funded by Société nationale française de médecine interne (SNFMI) and the Toulouse University Hospital.

  • Competing interests This study is academic. JM reports grants from SNFMI. GM received meeting attendance grants from Novartis and Amgen and is coordinator of research studies granted by CSL Behring, Novartis and Grifols. He participated in educational sessions funded by Amgen and Novartis, and boards for Novartis and Amgen.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles